Allogene Therapeutics logo

Allogene TherapeuticsNASDAQ: ALLO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

11 October 2018

Next earnings report:

01 November 2024

Last dividends:

N/A

Next dividends:

N/A
$585.45 M
-79%vs. 3y high
67%vs. sector
-vs. 3y high
-vs. sector
-62%vs. 3y high
43%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 21 min ago
$2.80-$0.02(-0.72%)

Dividend

No data over the past 3 years
$10.00 K$10.00 K

Analysts recommendations

Institutional Ownership

ALLO Latest News

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
globenewswire.com30 October 2024 Sentiment: -

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report third quarter 2024 financial results and provide a business update on November 7, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity
gurufocus.com02 October 2024 Sentiment: NEGATIVE

Allogene Therapeutics, Inc. (ALLO, Financial) saw a significant drop in its stock price, falling 5.06% to $2.54 per share. The trading volume reached 1.41 million shares, with a turnover rate of 0.67% and a volatility of 4.49%.

Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
seekingalpha.com30 September 2024 Sentiment: POSITIVE

Positive interim results released from phase 1/1b study using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory Multiple Myeloma. The global multiple myeloma market is projected to reach $44.22 billion by 2032. Interim data update for use of P-CD19CD20-ALLO1 in ongoing phase 1 study targeting patients with B-cell malignancies expected in the 2nd half of 2024 pending coordination with Roche.

ALLO Communications Lays Foundation for Groundbreaking Business and Residential Experiences Over 50G PON Delivered With the Calix Broadband Platform
businesswire.com24 September 2024 Sentiment: POSITIVE

SAN JOSE, Calif.--(BUSINESS WIRE)---- $CALX #calix--Today, Calix, Inc. (NYSE: CALX) reaffirmed the power of its cloud-and-software broadband platform to enable customers to simplify their business, innovate for their subscribers, and grow value for themselves and their communities. Supported by a trusted 15-year partnership, last week ALLO Communications and Calix conducted a 50G PON trial within the ALLO production network in Lincoln, Nebraska. The introduction of 50G PON on the Calix Broadband Platform will e.

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
prnewswire.com16 September 2024 Sentiment: POSITIVE

FDA evaluated RMAT application based on positive clinical data from ongoing Phase 1 study of P-BCMA-ALLO1; new clinical data from the study will be presented at the 21st International Myeloma Society Annual Meeting this month RMAT designation recognizes potential of P-BCMA-ALLO1 to address significant unmet needs of multiple myeloma patients and enables increased dialogue with FDA throughout the development process SAN DIEGO , Sept. 16, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to P-BCMA-ALLO1, an investigational stem cell memory T cell (TSCM)-based allogeneic CAR-T cell therapy in Phase 1/1b clinical development for the treatment of patients with relapsed/refractory multiple myeloma.

3 Hot Penny Stocks to Buy With $1000
247wallst.com07 September 2024 Sentiment: POSITIVE

Penny stocks are some of my favorite stocks to watch.

Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
zacks.com06 September 2024 Sentiment: POSITIVE

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript
seekingalpha.com10 August 2024 Sentiment: POSITIVE

Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Christine Cassiano - Executive Vice President, Chief Corporate Officer and IR David Chang - President, Chief Executive Officer and Co-Founder Zachary Roberts - Executive Vice President of Research & Development and Chief Medical Officer Geoffrey Parker - Executive Vice President and Chief Financial Officer Conference Call Participants Brian Chinn - JPMorgan Jenna Li - Jefferies Tyler Van Buren - TD Cowen Jack Allen - Baird Asthika Goonewardene - Truist Brooke Schuster - William Blair Matthew Biegler - Oppenheimer John Newman - Canaccord Benjamin Burnett - Stifel Luca Issi - RBC Capital Tashdid Hasan - Rodman & Renshaw Reni Benjamin - Citizens JMP Biren Amin - Piper Sandler William Pickering - Bernstein Operator Hello, and thank you for standing by. Welcome to Allogene Therapeutics' Second Quarter 2024 Conference Call.

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
zacks.com08 August 2024 Sentiment: POSITIVE

Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.

7 Biotech Stocks to Buy for Their Game-Changing Potential
investorplace.com08 August 2024 Sentiment: POSITIVE

With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.

  • 1(current)
  • 2
  • 3

What type of business is Allogene Therapeutics?

Allogene Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company's focus is on immuno-oncology - developing allogeneic T-cell therapy with gene editing for cancer treatment. Founded in 2017, the company's headquarters are located in South San Francisco, California. The company is developing T-cell candidates designed to target and destroy cancer cells. These T-cells are allogeneic, meaning they are obtained from healthy donors for potential use in any patient, rather than from an individual patient for that patient's use, as is the case with autologous T-cells. Allogene believes that this key difference will ultimately allow for faster, more reliable, and on a larger scale, providing accessible treatment to a greater number of patients.

What sector is Allogene Therapeutics in?

Allogene Therapeutics is in the Healthcare sector

What industry is Allogene Therapeutics in?

Allogene Therapeutics is in the Biotechnology industry

What country is Allogene Therapeutics from?

Allogene Therapeutics is headquartered in United States

When did Allogene Therapeutics go public?

Allogene Therapeutics initial public offering (IPO) was on 11 October 2018

What is Allogene Therapeutics website?

https://www.allogene.com

Is Allogene Therapeutics in the S&P 500?

No, Allogene Therapeutics is not included in the S&P 500 index

Is Allogene Therapeutics in the NASDAQ 100?

No, Allogene Therapeutics is not included in the NASDAQ 100 index

Is Allogene Therapeutics in the Dow Jones?

No, Allogene Therapeutics is not included in the Dow Jones index

When was Allogene Therapeutics the previous earnings report?

No data

When does Allogene Therapeutics earnings report?

The next expected earnings date for Allogene Therapeutics is 01 November 2024